article
Pharma Horizons: leading-edge formulation
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
List view / Grid view
Big Pharma
article
What will shape the Pharma landscape in Q3 2025?
Upcoming drug approvals and clinical progress will be pivotal during the third quarter of the year, says GlobalData.
news
Sanofi $1.6 billion acquisition to advance respiratory vaccines
The new deal could support innovation of next-generation combination vaccines to protect older adults against multiple respiratory viruses.
news
Boehringer partnership to advance biologic for rare skin condition
The new partnership between Boehringer Ingelheim and LEO Pharma aims to expand treatment access for more patients with generalised pustular psoriasis.
news
UK Government publishes Life Sciences Sector Plan
While a focus on accelerating access for innovative medicines has been welcomed, industry representatives caution that current system infrastructure could hinder the plans proposed by the UK Government.
news
Updated licensing agreement marks “major milestone” in global HIV response
The expanded agreement between ViiV Healthcare and Medicines Patent Pool (MPP) provides a more patient-centric treatment approach for HIV patients worldwide.
article
Supporting the pharmaceutical industry – how a CDMO can help
After their recent webinar, European Pharmaceutical Review’s Head of Content Ian Betteridge spoke with the team at Adragos Pharma to discuss the role of a CDMO and their importance in the fill and finish sector.
news
New Amgen data highlights promise in gastric cancer
The top-line Phase III findings illustrate potential of the monoclonal antibody plus chemotherapy as a first-line gastric cancer treatment.
news
Next drug patent cliff to challenge Big Pharma strategy
While the pharmaceutical market is expected to witness strong pricing competition, there is also significant opportunity for biotech companies, research says.
news
AbbVie immunology deal to advance potential first-in-class therapy
The new acquisition, worth up to $2.1 billion, gives AbbVie rights to a potential first-in-class drug for B cell-mediated autoimmune diseases.
news
Gilead partners to advance novel oral oncology drug
The deal between Gilead Sciences and Kymera Therapeutics could lead to development of safer and more effective cancer treatments.
article
Bioprocessing / Bioproduction In-Depth Focus 2025
This in-depth focus features articles on biosimilars and biomanufacturing in Europe, the potential of plant tissue-based bioproduction and utilising digital twins for optimisation of bioprocesses.
article
European Pharmaceutical Review Issue 2 2025
EPR Issue 2 includes articles on the impact of tariffs on the pharmaceutical supply chain, advances in bioprocessing, manufacturing and more.
news
Regulatory shift signals potential change for future CGT sector
The cell and gene therapy (CGT) sector must maintain its scientific rigor despite recent changes to US policy and market conditions, says key industry body.
news
NICE concludes decision for two Alzheimer’s treatments
The committee’s final draft guidance cited high-cost as a key reason for its negative opinion of the Alzheimer’s drugs, developed by Biogen and Eisai.
